Hims & Hers Health, Inc. (HIMS)
| Market Cap | 2.07B |
| Revenue (ttm) | 148.76M |
| Net Income (ttm) | -18.11M |
| Shares Out | 78.05M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $9.78 |
| Previous Close | $10.32 |
| Change ($) | -0.54 |
| Change (%) | -5.23% |
| Day's Open | 9.64 |
| Day's Range | 9.32 - 9.85 |
| Day's Volume | 540,711 |
| 52-Week Range | 9.32 - 25.40 |
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today announced ...
Shares of Hims & Hers Health, Inc. (NYSE:HIMS) are in trouble. The stock is testing critical support and if this support holds, shares may rally.
Here are three companies with exciting growth stories that just went public.
These companies are at the forefront of innovation in the healthcare sector, and their stocks are surprisingly affordable too.
Ignore the near-term pullback in Hims & Hers. With its unique business model, telehealth play HIMS stock remains a potential long-term winner.
Hims & Hers CEO on portfolio expansion opportunities, company outlook
Yahoo Finance's Brian Sozzi, Myles Udland, and Julie Hyman speak with Hims & Hers Co-founder & CEO Andrew Dudum about the company's first earnings report since going public.
Shares of the newly public company dropped on weak guidance in its fourth-quarter earnings report.
There are a lot of crosscurrents in the market right now.
Multi-specialty telehealth platform Hims & Hers Health, Inc. reported that revenue surged 67 percent from the fourth quarter of 2019 to the fourth quarter of 2020. “This is an organization built on soli...
Hims & Hers Health Inc. (NYSE: HIMS) reported its financial results for the fiscal fourth quarter on Thursday that came in better than what analysts had anticipated, despite the ongoing Coronavirus pand...
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today reported f...
SAN FRANCISCO--(BUSINESS WIRE)--Andrea Perez and Ambar Bhattacharyya join Hims & Hers Board of Directors to help the company pioneer a better way for patients to access healthcare.
A small company by the name of Conversion Labs (NASDAQ:CVLB) will be the eBay or Alibaba of the DTC telemedicine platforms space. The post This DTC Telemedicine Stock Has Enormous Potential Thanks to th...
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, will participate...
SPACs dominated Wall Street in 2020. The backwards IPOs of these three companies suggests that 2021 will be more of the same.
Telehealth is the future, and Hims & Hers looks well-positioned for that future. Growth should keep the rally in HIMS stock going.
The prospects for HIMS stock look good. The company has certainly built a robust platform.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, will release fis...
If you believe in the future of telemedicine, then keep an eye on HIMS stock. It might not be in the buy zone yet, though, so be patient.
The company has had early success in building a customer base as well as infrastructure to support their demand. HIMS offers frictionless patient to consumer experiences that are cost efficient and comp...
With its focus on millennials, fast growing telemedicine play HIMS stock has plenty of room to run after its recent SPAC merger. The post Buy Hims & Hers Stock for a Solid Play on Telehealth appeared fi...
Hims & Hers CEO on $1.6 billion SPAC deal and goal to provide affordable health care
Hims & Hers Co-Founder and CEO Andrew Dudum joins Yahoo Finance's Brain Sozzi and Julie Hyman to discuss the company's $1.6 billion SPAC deal with Oaktree Capital Management and discuss the future of me...
Hims & Hers, a San Francisco-based telehealth startup that sells sexual wellness and other health products and services to millennials, began trading publicly today on the NYSE after completing a revers...
Telehealth play HIMS stock makes its debut today. Here's what you should know about newly public Hims & Hers now.
About HIMS
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's cu... [Read more...]
| Industry Household & Personal Products | Founded 2017 |
| Stock Exchange NYSE | Ticker Symbol HIMS |
Financial Performance
In 2020, HIMS's revenue was $148.76 million, an increase of 80.18% compared to the previous year's $82.56 million. Losses were -$18.11 million, -74.86% less than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for HIMS is 16.50, which is an increase of 68.71% from the latest price.